Ticagrelor in the Management of Coronary Artery Disease

• DOI: 10.2217/fca-2020-0108
• Publication Date: 2020-09-22T13:25:48Z
• Authors: Krithika Loganath; Philip D Adamson; Alastair J Moss
• Keywords: Pharmacodynamics

Ticagrelor is a potent and orally active P2Y12 inhibitor. has been extensively tested in Phase II III trials patients with coronary artery disease. The pharmacokinetics pharmacodynamics of ticagrelor result more rapid effective inhibition platelet activation compared other inhibitors. This resulted reduction recurrent major cardiovascular events initial randomized controls comparing clopidogrel. More recently, clinical have investigated the use stable disease high residual risk thrombotic events. In disease, antiplatelet effect counterbalanced by an increased bleeding. Further research ongoing to determine optimal duration therapy.